Wall Street analysts’ estimates
Wall Street analysts expect Pfizer’s (PFE) top line to increase ~0.7% to ~$13.72 billion in 4Q17. The EPS (earnings per share) is expected to increase to $0.56 for 4Q17.
The above chart shows analysts’ recommendations for Pfizer stock in the last 12 months.
Pfizer’s stock price has increased nearly 16.2% in the last 12 months. Analysts’ estimates show that the stock could return ~4.4% in the next 12 months. Wall Street analysts’ recommendations show a 12-month target price of $38.57 per share—compared to the last price of $36.93 per share as of January 22, 2018.
As of January 24, 2018, there are 24 analysts tracking Pfizer. Of the analysts, 13 recommended a “buy,” nine recommended a “hold,” and two recommended a “sell.” The consensus rating for Pfizer stands at 2.54, which represents a moderate buy for value investors. Changes in analysts’ estimates and recommendations are based on changing trends in the stock price and the company’s performance.
As of January 23, 2018, Pfizer trades at a forward PE (price-to-earnings) multiple of 13.2x—compared to the industry average of 18.3x. Pfizer trades at a forward EV-to-EBITDA of 10.8x—compared to the industry average of 12.8x.
Notably, the iShares US Pharmaceuticals ETF (IHE) holds 81.2% of its total investments in pharmaceutical companies, 14.8% in biotechnology companies, and 4% of in drug retailers, medical equipment, and biotherapeutic drug companies. IHE holds 8.1% in Pfizer, 6.1% in Bristol-Myers Squibb (BMY), 5.5% in Eli Lilly (LLY), and 7.7% in Merck & Co. (MRK).